Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Your search for FMC7 returned no results
Showing 101 to 150 of 475 results for face

  1. Skin cancer prevention (PH32)

    This guideline covers new buildings and communal outdoor areas. The aim is to ensure there are enough shady areas to protect people from overexposure to the sun.

  2. Multiple sclerosis (QS108)

    This quality standard covers diagnosing and managing multiple sclerosis (MS) in adults. It includes care, support and review for people with MS. It describes high-quality care in priority areas for improvement.

  3. Healthy workplaces: improving employee mental and physical health and wellbeing (QS147)

    This quality standard covers the health and wellbeing of all employees, including their mental health. It describes high-quality care in priority areas for improvement. It does not cover managing long-term sickness absence.

  4. Powered microdebrider turbinoplasty for inferior turbinate hypertrophy (HTG347)

    Evidence-based recommendations on powered microdebrider turbinoplasty for inferior turbinate hypertrophy. This involves cutting away some of the swollen membrane covering the turbinates.

  5. Devices for remote monitoring of Parkinson's disease (HTG657)

    Evidence-based recommendations on Kinesia 360 and KinesiaU (Great Lakes NeuroTechnologies), PDMonitor (PD Neurotechnology), Personal KinetiGraph (Global Kinetics) and STAT-ON (Sense4care) for remote monitoring of Parkinson’s disease.

  6. Virtual reality technologies for treating agoraphobia or agoraphobic avoidance: early value assessment (HTG701)

    Early value assessment (EVA) guidance on virtual reality technologies for treating agoraphobia or agoraphobic avoidance.

  7. Learning disabilities and behaviour that challenges: service design and delivery (NG93)

    This guideline covers services for children, young people and adults with a learning disability (or autism and a learning disability) and behaviour that challenges. It aims to promote a lifelong approach to supporting people and their families and carers, focusing on prevention and early intervention and minimising inpatient admissions.

  8. Needle and syringe programmes (PH52)

    This guideline covers needle and syringe programmes for people (including those under 16) who inject drugs. The main aim is to reduce the transmission of viruses and other infections caused by sharing injecting equipment, such as HIV, hepatitis B and C. In turn, this will reduce the prevalence of blood-borne viruses and bacterial infections, so benefiting wider society.

  9. Brentuximab vedotin in combination for untreated stage 3 or 4 CD30-positive Hodgkin lymphoma (TA1059)

    Evidence-based recommendations on brentuximab vedotin (Adcetris) for untreated stage 3 or 4 CD30-positive Hodgkin lymphoma in adults.

  10. Suspected neurological conditions: recognition and referral (NG127)

    This guideline covers the initial assessment of symptoms and signs that might indicate a neurological condition. It helps non-specialist healthcare professionals to identify people who should be offered referral for specialist investigation.

  11. Adrenal insufficiency: identification and management (NG243)

    This guideline covers identifying and managing adrenal insufficiency (hypoadrenalism) in babies, children, young people and adults. It aims to improve the treatment of primary, secondary and tertiary adrenal insufficiency, and the prevention and management of adrenal crisis.

  12. Study NICE and LSE's Executive MSc Healthcare Decision-Making

    Study NICE and LSE's Executive MSc Healthcare Decision-Making

  13. Study NICE and LSE's Executive MSc Healthcare Decision-Making

    Study NICE and LSE's Executive MSc Healthcare Decision-Making

  14. NICE Listens

    NICE Listens is our programme of deliberative public engagement. It's used to give us an understanding of public opinion on moral, ethical and social value issues.

  15. Drug misuse prevention: targeted interventions (NG64)

    This guideline covers targeted interventions to prevent misuse of drugs, including illegal drugs, ‘legal highs’ and prescription-only medicines. It aims to prevent or delay harmful use of drugs in children, young people and adults who are most likely to start using drugs or who are already experimenting or using drugs occasionally.

  16. Pressure ulcers (QS89)

    This quality standard covers preventing, assessing and managing pressure ulcers (bed sores) in adults, young people and children. It includes risk assessment and support to prevent pressure ulcers. It applies to all settings, including hospitals, care homes (with and without nursing care) and people’s own homes.

  17. Pneumonia: diagnosis and management (QS110)

    This quality standard covers diagnosing, assessing and treating community-acquired and hospital-acquired pneumonia in babies over 1 month (corrected gestational age), children, young people and adults. It describes high-quality care in priority areas for improvement. It does not cover ventilator associated pneumonia or COVID-19 pneumonia.

  18. Early and locally advanced breast cancer: diagnosis and management (NG101)

    This guideline covers diagnosing and managing early and locally advanced breast cancer. It aims to help healthcare professionals offer the right treatments to people, taking into account the person's individual preferences.

  19. Corticosteroid-eluting bioabsorbable stent or spacer insertion during endoscopic sinus surgery to treat chronic rhinosinusitis (HTG407)

    Evidence-based recommendations on corticosteroid-eluting bioabsorbable stent or spacer insertion during endoscopic sinus surgery for chronic rhinosinusitis in adults. This involves putting a stent (short tube) into the sinus to improve drainage.

  20. YAG laser vitreolysis for symptomatic vitreous floaters (HTG644)

    Evidence-based recommendations on YAG laser vitreolysis for symptomatic vitreous floaters. This involves a special type of laser (YAG) firing short pulses of energy into the floaters, to break them up (vitreolysis) and reduce sight disturbances.

  21. Children's attachment: attachment in children and young people who are adopted from care, in care or at high risk of going into care (NG26)

    This guideline covers the identification, assessment and treatment of attachment difficulties in children and young people up to age 18 who are adopted from care, in special guardianship, looked after by local authorities in foster homes (including kinship foster care), residential settings and other accommodation, or on the edge of care. It aims to address the many emotional and psychological needs of children and young people in these situations, including those resulting from maltreatment.

  22. Head and neck cancer (QS146)

    This quality standard covers assessing, diagnosing and managing head and neck cancer, including cancer of the upper aerodigestive tract in people aged 16 or over. It describes high-quality care in priority areas for improvement.

  23. Tebentafusp for treating advanced uveal melanoma (TA1027)

    Evidence-based recommendations on tebentafusp (Kimmtrak) for treating uveal melanoma in adults.

  24. Hypoglossal nerve stimulation for moderate to severe obstructive sleep apnoea (HTG455)

    Evidence-based recommendations on hypoglossal nerve stimulation for moderate to severe obstructive sleep apnoea in adults. This involves implanting a device under the skin in the chest and connecting it to a nerve under the tongue (hypoglossal nerve).

  25. Gambling-related harms: identification, assessment and management (NG248)

    This guideline covers identifying, assessing and treating gambling-related harms. This includes people aged 18 and over who are experiencing gambling that harms, and people of any age affected by someone close to them who is experiencing gambling that harms.

  26. Brodalumab for treating moderate to severe plaque psoriasis (TA511)

    Evidence-based recommendations on brodalumab (Kyntheum) for treating moderate to severe plaque psoriasis in adults.

  27. Advocacy services for adults with health and social care needs (NG227)

    This guideline covers advocacy for people using health and social care services in all adult settings (including young people under 18 using adult services). It describes how to commission and deliver effective advocacy, as well as identifying who should be offered advocacy (including who is legally entitled to it). It also covers monitoring and improving advocacy services, and training and skills for advocates and practitioners.

  28. Mechanical clot retrieval for treating acute ischaemic stroke (HTG403)

    Evidence-based recommendations on mechanical clot retrieval for treating acute ischaemic stroke in adults. This involves using a device to remove the blood clot from the brain to restore normal blood flow.

  29. Endoscopic thoracic sympathectomy for primary facial blushing (HTG331)

    Evidence-based recommendations on endoscopic thoracic sympathectomy for primary facial blushing. This involves cutting off nerve signals to stop the blushing.

  30. Community engagement: improving health and wellbeing and reducing health inequalities (NG44)

    This guideline covers community engagement approaches to reduce health inequalities, ensure health and wellbeing initiatives are effective and help local authorities and health bodies meet their statutory obligations.

  31. Balloon catheter dilation of paranasal sinus ostia for chronic sinusitis (HTG174)

    Evidence-based recommendations on balloon catheter dilation of paranasal sinus ostia for chronic sinusitis. This involves gently inflating a small balloon, which is introduced through the nose via a flexible tube, to help keep the sinus passages open and unobstructed.

  32. Otitis media with effusion in under 12s (NG233)

    This guideline covers identifying and managing otitis media with effusion (OME), also known as ‘glue ear’, in children younger than 12 years. It aims to improve hearing and quality of life in children with OME.

  33. Tobacco: preventing uptake, promoting quitting and treating dependence (NG209)

    This guideline covers support to stop smoking for everyone aged 12 and over, and help to reduce people's harm from smoking if they are not ready to stop in one go. It also covers ways to prevent children, young people and young adults aged 24 and under from taking up smoking.

  34. Rheumatoid arthritis in over 16s (QS33)

    This quality standard covers assessing, diagnosing and managing rheumatoid arthritis in over 16s. It describes high-quality care in priority areas for improvement.

  35. CFHealthHub for managing cystic fibrosis during the COVID-19 pandemic (MIB219)

    NICE has developed a medtech innovation briefing (MIB) on CFHealthHub for managing cystic fibrosis during the COVID-19 pandemic .

  36. Frequency of application of topical corticosteroids for atopic eczema (TA81)

    Evidence-based recommendations on using topical corticosteroids for people with atopic eczema.

  37. Therapeutic hypothermia for acute ischaemic stroke (HTG511)

    Evidence-based recommendations on therapeutic hypothermia for acute ischaemic stroke in adults. This involves using a cooling device to reduce the body’s temperature after a stroke.

  38. Mental wellbeing at work (NG212)

    This guideline covers how to create the right conditions for mental wellbeing at work. It aims to promote a supportive and inclusive work environment, including training and support for managers and helping people who have or are at risk of poor mental health.

  39. Human and animal bites: antimicrobial prescribing (NG184)

    This guideline sets out an antimicrobial prescribing strategy for human and animal bites (excluding insect bites) in adults, young people and children aged 72 hours and over. It aims to optimise antibiotic use and reduce antibiotic resistance.

  40. Cerebral palsy in adults (QS191)

    This quality standard covers care and support for adults with cerebral palsy (aged 25 and over). It describes high-quality care in priority areas for improvement.

  41. Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma (TA540)

    Evidence-based recommendations on pembrolizumab (Keytruda) for treating relapsed or refractory classical Hodgkin lymphoma in adults.

  42. ENDURALIFE powered CRT-D devices for treating heart failure (HTG433)

    Evidence-based recommendations on ENDURALIFE-powered CRT-D devices for treating heart failure.

  43. Child maltreatment: when to suspect maltreatment in under 18s (CG89)

    This guideline covers the signs of possible child maltreatment in children and young people aged under 18 years. It aims to raise awareness and help healthcare professionals who are not child protection specialists to identify the features of physical, sexual and emotional abuse, neglect and fabricated or induced illness.

  44. Urinary incontinence and pelvic organ prolapse in women: management (NG123)

    This guideline covers assessing and managing urinary incontinence and pelvic organ prolapse in women aged 18 and over. It also covers complications associated with mesh surgery for these conditions.

  45. Self-harm: assessment, management and preventing recurrence (NG225)

    This guideline covers assessment, management and preventing recurrence for children, young people and adults who have self-harmed. It includes those with a mental health problem, neurodevelopmental disorder or learning disability and applies to all sectors that work with people who have self-harmed.

  46. Effectiveness of digital technologies:- How effective and cost effective are digital technologies, such as web-based interventions, online self-assessment or targeted new media, for drug misuse prevention among groups at risk in the UK?

    digital technology are potentially more cost effective than those delivered face to face and could be used for prevention...

  47. Stereotactic radiosurgery for trigeminal neuralgia (HTG608)

    Evidence-based recommendations on stereotactic radiosurgery for trigeminal neuralgia in adults. This involves focusing radiation on the trigeminal nerve to damage it, thereby relieving pain.

  48. Lateral elbow resurfacing for arthritis (HTG591)

    Evidence-based recommendations on lateral elbow resurfacing for arthritis. This involves inserting an implant into the 2 bones that form the joint at the outer part of the elbow, under general anaesthetic.

  49. Interstitial photodynamic therapy for malignant parotid tumours (HTG166)

    Evidence-based recommendations on interstitial photodynamic therapy for malignant parotid tumours. This involves injecting a photosensitising agent into a vein and using a special light to activate it and destroy the tumour cells.